新诊断乳腺癌动态首过18F-FDG PET/CT肿瘤灌注及其异质性的生物学关联
结果显示淋巴结受累肿瘤灌注更高而SUV无差异,TN型代谢活性更高但整体BF无差异,HER2型灌注与代谢异质性更大,且灌注异质性与代谢异质性相关。
要点
- 淋巴结受累乳腺癌灌注更高,而SUV_max与SUV_mean无显著差异。
- TN型肿瘤代谢活性高于HER2型与Luminal型,但整体BF值无显著差异。
- HER2型肿瘤灌注与代谢异质性均大于Luminal型与TN型,灌注异质性与代谢异质性相关。
核心结论
- 乳腺癌灌注在大肿瘤及淋巴结受累肿瘤中更高,且不与肿瘤整体代谢的相近改变平行。
- 灌注异质性与代谢异质性相关,提示肿瘤灌注及血管生成过程可能参与乳腺癌既往所见的代谢异质性。
研究设计与样本
- 静脉注射3 MBq/kg 18F-FDG后即刻行2分钟胸部动态采集,90分钟后行两步静态采集,用单室动力学模型以ml/min/g计算肿瘤BF。
- 提取描述肿瘤灌注与代谢异质性的纹理特征(TF),按Luminal(HR+/HER2-)、HER2(HER2+)、TN(HR-/HER2-)分组比较。
主要发现
- 淋巴结受累肿瘤灌注更高,而SUV_max或SUV_mean无显著差异。
- TN型肿瘤代谢活性高于HER2型与Luminal型,但整体BF值无显著差异。
- HER2型肿瘤灌注与代谢异质性均大于Luminal型与TN型,灌注异质性与代谢异质性相关性良好。
临床怎么用
- 对新诊断乳腺癌可考虑在治疗前18F-FDG PET/CT中加入动态首过采集以评估肿瘤BF及灌注异质性。
- 解读灌注参数时需结合肿瘤大小、淋巴结状态及分子亚型,灌注与整体代谢信息不可互相替代。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this prospective study is to analyze the global tumor blood flow (BF) and its heterogeneity in newly diagnosed breast cancer (BC) according to tumor biological characteristics and molecular subtypes. These perfusion parameters were compared to those classically derived from metabolic studies to investigate links between perfusion and metabolism. METHODS: Two hundred seventeen newly diagnosed BC patients underwent a 18F-FDG PET/CT exam before any treatment. A 2-min dynamic acquisition, centered on the chest, was performed immediately after intravenous injection of 3 MBq/kg of 18F-FDG, followed by a two-step static acquisition 90 min later. Tumor BF was calculated (in ml/min/g) using a single compartment kinetic model. In addition to standard PET parameters, texture features (TF) describing the heterogeneity of tumor perfusion and metabolism were extracted. Patients were divided into three groups: Luminal (HR+/HER2-), HER2 (HER2+), and TN (HR-/HER2-). Global and TF parameters of BF and metabolism were compared in different groups of patients according to tumor biological characteristics. RESULTS: Tumors with lymph node involvement showed a higher perfusion, whereas no significant differences in SUV_max or SUV_mean were reported. TN tumors had a higher metabolic activity than HER2 and luminal tumors but no significant differences in global BF values were noted. HER2 tumors exhibited a larger tumor heterogeneity of both perfusion and metabolism compared to luminal and TN tumors. Heterogeneity of perfusion appeared well correlated to that of metabolism. CONCLUSIONS: The study of breast cancer perfusion shows a higher BF in large tumors and in tumors with lymph node involvement, not paralleled by similar modifications in tumor global metabolism. In addition, the observed correlation between the perfusion heterogeneity and the metabolism heterogeneity suggests that tumor perfusion and consequently the process of tumor angiogenesis might be involved in the metabolism heterogeneity previously shown in BC.
引用
- Payan N, Presles B, Brunotte F, et al. Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019. PMID: 31396665. doi:10.1007/s00259-019-04422-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。